Por favor, use este identificador para citar o enlazar este ítem:
http://dspace.udla.edu.ec/handle/33000/8047
Tipo de material : | bachelorThesis |
Título : | Desarrollo de un método rápido de detección de streptococcus agalactiae en muestras clínicas mediante la técnicas de PCR |
Autor : | Calle Mendoza, Pamela Dayana |
Tutor : | Cordero Arroyo, Andrea Paola |
Palabras clave : | TÉCNICAS GENÉTICAS;PCR;MICROORGANISMOS |
Fecha de publicación : | 2017 |
Editorial : | Quito: Universidad de las Américas, 2017 |
Citación : | Calle Mendoza, P. D. (2017). Desarrollo de un método rápido de detección de streptococcus agalactiae en muestras clínicas mediante la técnica de pcr (Tesis de pregrado). Universidad de las Américas, Quito. |
Resumen : | Streptococcus agalactiae GBS es una bacteria beta hemolítica y gram positiva causante de enfermedades invasivas, sepsis y meningitis en neonatos, infantes, mujeres embarazadas y adultos inmunológicamente comprometidos... |
Descripción : | Streptococcus agalactiae (GBS) is a beta hemolytic and gram positive bacteria causing invasive diseases, sepsis and meningitis to neonates, infants, pregnant women and immunologically compromised adults. The ‘gold standard’ diagnostic method consists on sample culture and subsequent morphologic identification. The treatment and/or prophylactic methods for GBS infections are based on dosage of penicillin and ampicillin or erythromycin and clindamycin as alternative treatments in case of anaphylaxis. This project focuses on the development of a rapid detection method for Streptococcus agalactiae by PCR amplification of the scpB gene with samples of Staphylococcus aureus and Escherichia coli as negative controls, as well as susceptibility analysis to antimicrobials complemented by the PCR amplification of resistance genes mreA and ermB. 132 samples from different human tissues or fluids belonging to patients previously diagnosed with infection or colonization by GBS from 2012 to 2016, were analyzed. Effectivity of the scpB gene for S. agalactiae identification was proven with a sensitivity percentage of 96 percent. Furthermore, it was determined that the ermB gene is more related to both the erythromycin resistance and the crossresistance MLSB phenotype, than the mreA gene. Even though the resistance phenotypes to erythromycin and clindamycin did not show a statistical significance variance (p equal 0.21) within the time considered in this investigation, the undeniable increasing resistance to both antibiotics was well proven. It can therefore be concluded that the scpB gene can be used as a detection factor for GBS independently of the sample treated. It is also recommended to run susceptibility tests before an infected patient is dosed with erythromycin or clindamycin. Given that the resistance to these compounds are coded in mobile elements, it can be established that this phenotype will continue to increase with time. |
URI : | http://dspace.udla.edu.ec/handle/33000/8047 |
Aparece en las colecciones: | Ingeniería en Biotecnología |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
UDLA-EC-TIB-2017-35.pdf | 2,64 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons